DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its ...
Please provide your email address to receive an email when new articles are posted on . The acceptance paves the way for a pending phase 2b/3 clinical trial of COMP360 in PTSD. The manufacturer plans ...
Serpin Pharma receives FDA IND approval for SP16, a novel therapy for chemotherapy-induced peripheral neuropathy. Phase ...
Partnering with Parent Project Muscular Dystrophy to ensure timely access to the trial for eligible patients~15,000 children are living with DMD ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...
The US Food and Drug Administration (FDA) on Tuesday issued draft guidance requiring sponsors to submit investigational new drug (IND) safety reports for serious and unexpected suspected adverse ...
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial Compass continues to advance ...
IND Filing and Concurrent RMAT Request Position XytriX™ as a Potential Breakthrough Biotherapeutic for More Than 500 Million People Living with Osteoarthritis Our concurrent request for RMAT ...
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) and its CNS-oncology focused wholly owned subsidiary Starlight Therapeutics today announced that the U.S. Food and Drug Administration (FDA) ...
Working with Parent Project Muscular Dystrophy and the Duchenne Registry on patient identification and trial awareness efforts ~15,000 children ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results